Identification of a permissible HLA mismatch in hematopoietic stem cell transplantation

Blood. 2014 Feb 20;123(8):1270-8. doi: 10.1182/blood-2013-10-532671. Epub 2014 Jan 9.

Abstract

In subjects mismatched in the HLA alleles C*03:03/C*03:04 no allogeneic cytotoxic T-lymphocyte responses are detected in vitro. Hematopoietic stem cell transplantation (HSCT) with unrelated donors (UDs) showed no association between the HLA-C allele mismatches (CAMMs) and adverse outcomes; antigen mismatches at this and mismatches other HLA loci are deleterious. The absence of effect of the CAMM may have resulted from the predominance of the mismatch C*03:03/C*03:04. Patients with hematologic malignancies receiving UD HSCT matched in 8/8 and 7/8 HLA alleles were examined. Transplants mismatched in HLA-C antigens or mismatched in HLA-A, -B, or -DRB1 presented significant differences (P < .0001) in mortality (hazard ratio [HR] = 1.37, 1.30), disease-free survival (HR = 1.33, 1.27), treatment-related mortality (HR = 1.54, 1.54), and grade 3-4 acute graft-versus-host disease (HR = 1.49, 1.77) compared with the 8/8 group; transplants mismatched in other CAMMs had similar outcomes with HR ranging from 1.34 to 172 for these endpoints. The C*03:03/C*03:04 mismatched and the 8/8 matched groups had identical outcomes (HR ranging from 0.96-1.05). The previous finding that CAMMs do not associate with adverse outcomes is explained by the predominance (69%) of the mismatch C*03:03/03:04 in this group that is better tolerated than other HLA mismatches.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Algorithms
  • Alleles
  • Child
  • Child, Preschool
  • Graft vs Host Disease / epidemiology*
  • Graft vs Host Disease / genetics
  • Graft vs Host Disease / immunology
  • HLA-C Antigens / genetics*
  • HLA-C Antigens / immunology
  • Hematologic Neoplasms / epidemiology*
  • Hematologic Neoplasms / genetics
  • Hematologic Neoplasms / therapy*
  • Hematopoietic Stem Cell Transplantation / adverse effects
  • Hematopoietic Stem Cell Transplantation / methods*
  • Histocompatibility Testing / methods*
  • Humans
  • Infant
  • Middle Aged
  • Multivariate Analysis
  • Prevalence
  • Risk Factors
  • Unrelated Donors
  • Young Adult

Substances

  • HLA-C Antigens